Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RVMD
SELLRevolution Medicines, Inc. · Healthcare · United States · $40.2B · Avg Vol: $526M/d
COMPANY DESCRIPTION
Revolution Medicines, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for RAS-addicted cancers using its proprietary RAS(ON) inhibitor platform. Its innovative approach to directly target oncogenic RAS proteins, historically considered undruggable, positions it at the forefront of cancer drug development. The company is a specialized oncology biotech pioneering novel small molecule inhibitors for a challenging class of cancer targets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 35.4M | 11.6M | 0 | 0 | -67.3% | — | 103.3M | 881.2M | 195.4% |
| EPS | -1.31 | -3.86 | -3.58 | -5.95 | — | -6.89 | -8.07 | -5.80 | — |
| Shares | 212.6M | 164.7M | 185.9M | 197.0M | -7.3% | 212.6M | — | — | — |
| Debt | 64.2M | 87.9M | 135.8M | 158.7M | 35.2% | 437.3M | — | — | — |
| Equity | 685.2M | 1.8B | 2.3B | 1.6B | 33.5% | — | — | — | — |
| Op CF | -224.4M | -350.6M | -557.4M | -897.7M | — | -1.1B | — | — | — |
| Inv CF | -24.1M | -342.6M | -554.4M | 118.1M | — | — | — | — | — |
| Fin CF | 301.4M | 1.2B | 959.4M | 621.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RVMD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RVMD | Revolution Medicines, Inc.(you) | $40.2B | 25 | SELL |
| ALNY | Alnylam Pharmaceuticals, Inc. | $36.3B | 30 | SELL |
| MRNA.MX | Moderna, Inc. | $26.4B | 27 | SELL |
| 0JDM.L | IQVIA Holdings Inc. | $45.6B | 44 | HOLD |
| 0J8P.L | IDEXX Laboratories, Inc. | $66.0B | 37 | HOLD |
| CYTK | Cytokinetics, Incorporated | $11.0B | 26 | SELL |
| 0LTI.L | Waters Corporation | $29.9B | 48 | HOLD |
| KYMR | Kymera Therapeutics, Inc. | $9.1B | 25 | SELL |
| BBIO | BridgeBio Pharma, Inc. | $16.5B | 37 | HOLD |
| 0JAV.L | Insmed Incorporated | $18.9B | 10 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%